NCT06079983 2025-09-12
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
Clinical Trials
9 trialsNCT07008976 2025-08-14
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT07003074 2025-06-25
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT06929325 2025-04-16
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT03936933 2025-02-17
Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer
Eurofarma Laboratorios S.A.
Phase 3 Terminated
NCT06143553 2024-11-29
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06561607 2024-08-20
A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Not yet recruiting
NCT05755048 2023-09-01
FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3 Unknown
NCT01479244 2017-02-27
PRESENT
Galena Biopharma, Inc.
Phase 3 Completed